Recruiting
Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
ClinicalTrials.gov IDNCT04985058
PhaseNot Applicable
Enrollment108
SponsorHellenic Cooperative Oncology Group
Age18 Years and older
SexALL
Conditions studied
Breast Cancer
About this study
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
Primary outcomes
- Progression-free survival (Through the completion of the study, for an average of 6 months)
Eligibility information
Inclusion Criteria:
* Histologically confirmed HR-positive, HER2-negative breast cancer
* Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
* 18 years or older
* Any menopausal status
* Treatment with abemaciclib in combination with endocrine therapy
* Any endocrine therapy
* At least two months of treatment with abemaciclib
Study locations
- Hellenic Oncology Cooperative Group, Athens, Greece
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.